Diversified healthcare giant Johnson & Johnson (NYSE:JNJ) reported first-quarter profits on April 19 that beat analyst projections. The stock rallied a bit on the good news and pharmaceutical drug sales came in strong on new product launches. However, product recall costs continue to plague the company and growth trends have been anemic for several years now. Until J & J starts posting more consistent operating trends, a number of rivals look like better investment candidates.
TUTORIAL: Advanced Financial Statement Analysis

J&J's First-Quarter Recap
In the first quarter of 2011, total sales rose a modest 3.5% to $16.2 billion as organic growth of 1.8% combined with positive currency fluctuations of 1.7% to boost international and total company growth. The pharmaceutical division was the stand-out, with 7.5% growth to account for 37.5% of total sales as management stated sales of new drugs, including Stelara for the treatment of psoriasis and Simpon for the treatment of arthritis, posted strong performance. The medical device unit also posted decent growth as sales rose 3.3% to make up 39.8% of total sales on strong trends in glucose monitoring devices, disposable contact lenses and surgical care products.

The consumer unit made up the rest of the top line and saw sales fall 2.2% as product recalls, particularly in the McNeil Consumer Healthcare division, dented domestic sales by 13.8%. International sales continued to do well in the unit, rising 5.9%.

Reported net income fell 23.2% to $3.5 billion and earnings fell 22.8% to $1.25 per diluted share. The current quarter contained one-time litigation and recall charges, as did last year's first quarter. Backing out these non-recurring items, management estimated that earnings were $3.7 billion and $1.35 per diluted share, representing year-over-year growth in the low single digits.

Outlook for Johson & Johnson
Analysts currently project full-year sales growth of just over 4% and total sales of just over $64 billion. The company increased its earnings guidance and now expects full-year recurring profits between $4.90 and $5 per share for modest year-over-year growth of a couple of percent.

The strong pharma trends in Q1 are an encouraging sign for J&J and the company is staying active on the acquisition trail as well. It recently confirmed that management is talking with Swiss medical device firm Synthes about a potential $20 billion deal.

The Bottom Line
Despite its near-term woes, J&J remains extremely profitable. It didn't provide first-quarter balance sheet or cash flow data, but ended 2010 with close to $20 billion in net cash on the balance sheet and generated $14.5 billion in free cash flow, or approximately $5.21 per diluted share. (To learn more, see Free Cash Flow: Free, But Not Always Easy.)

J&J's forward earnings multiple continues to look appealingly low at about 12.4, but tangible signs of sustained sales growth and consistent profit expansion are still absent. As such, purer play rivals including Medtronic (NYSE:MDT), Teva Pharmaceuticals (Nasdaq:TEVA), Novartis (NYSE:NVS) and Stryker (NYSE:SYK) all look to have equally reasonable valuations given their projected growth rates over the longer haul.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  2. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  3. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  4. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  5. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  6. Investing

    What’s the Difference Between Duration & Maturity?

    We look at the meaning of two terms that often get confused, duration and maturity, to set the record straight.
  7. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  8. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  9. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  10. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center